Sponsors (76)
The bill prioritizes speeding development and access to ALS and other rare‑disease therapies and improving oversight and coordination, but does so at the cost of new federal spending, changed grant/data rules that create uncertainty for some applicants, and heightened safety/privacy and implementation risks if protections and funding are not adequately provided.
Patients with ALS and other rare diseases are likely to get faster access to new therapies because the bill strengthens grant and regulatory support, creates a 5‑year FDA action plan, and mandates GAO oversight to drive treatment development and access.
Researchers, developers, and companies will gain clearer expectations, increased grant/contract authority, and greater transparency on FDA priorities (including counting planned phase 2/3 trials), improving planning, investment decisions, and the likelihood that promising trials get funded.
Families, patient communities, and Congress will get better coordination, engagement, and evidence — through required FDA outreach approaches and an updated GAO analysis — which improves oversight and the information base for future policy decisions.
Patients and health systems face safety and privacy risks because accelerating regulatory pathways and requiring interim data reporting could weaken post‑market safety monitoring, threaten trial integrity or patient privacy if not tightly protected, and some planned actions in the FDA plan may be limited if additional funding is not provided.
Changes to grant eligibility and how participating trials are counted (including planned but not yet enrolling trials) may narrow or shift who receives support, creating uncertainty and potentially leaving some patients, researchers, or developers without expected funding.
Taxpayers could face higher federal spending and modest additional administrative costs to prepare and implement the FDA plan and GAO report (possible deficit impacts or crowding out of other priorities if not offset).
Based on analysis of 5 sections of legislative text.
Amends and reauthorizes programs to broaden what counts as participating clinical trials, permit FDA review of enrollment and interim data for certain grants, require a new 5‑year FDA action plan, and mandate a GAO report.
Introduced April 6, 2026 by Mike Quigley · Last progress April 6, 2026
Reauthorizes and amends the federal program aimed at accelerating development of therapies for ALS and other rare neurodegenerative diseases. It expands what counts as a participating clinical trial, lets the Department of Health and Human Services/FDA review trial enrollment and request interim data when renewing certain grants, requires the FDA to publish an updated five‑year action plan and assessment of its 2022 rare neurodegenerative diseases action plan within one year, and directs the Government Accountability Office to deliver a multi‑year evaluation report within four years. One amendment in this bill replaces unspecified text in the prior law (the exact replacement text was not provided in the excerpt), and the Committee expresses support for direct appropriations to carry out the Act’s provisions. The bill focuses on grant review standards, trial definitions, agency planning and public reporting, and an independent evaluation of program progress.